Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation In Vivo

Yunfeng Sun; Honghua Pan; Shenghui Shen; Zhongni Xia; Zhongmin Yu; ChengLe Li; Pingping Sun; Chuanwei Xin

doi:10.12659/MSM.921738

16 July 2020: Animal Study

Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation

Yunfeng Sun ^12AEG , Honghua Pan ^12CD , Shenghui Shen ^23ABCF , Zhongni Xia ^12BC , Zhongmin Yu ^2ABCD , ChengLe Li ^12F , Pingping Sun ^12DEG* , Chuanwei Xin ^12DG*

DOI: 10.12659/MSM.921738

Med Sci Monit 2020; 26:e921738

Authors information Article notes Copyright and License information

View HTML version

Supplementary Table 1 Primary antibodies used for Western blot.

No.	Target	Dilution	Source
1	α-SMA	1: 1000	ab5694	Abcam
2	Nrf-2	1: 1000	ab62352	Abcam
3	P65	1: 1000	ab16502	Abcam
4	JunD	1: 1000	ab28837	Abcam
5	α-tubulin	1: 1000	66031-1-Ig	PROTEINTECH
6	PCNA	1: 1000	10205-2-AP	PROTEINTECH

Back to the Article

Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation

Your Privacy